{"organizations": [], "uuid": "493c4f69045b6f52180398bc7bb6ea57f8779965", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-reata-pharmaceuticals-inc-announce/brief-reata-pharmaceuticals-inc-announces-q4-loss-per-share-0-64-idUSASB0C8LL", "country": "US", "domain_rank": 408, "title": "BRIEF-Reata Pharmaceuticals Inc. Announces Q4 Loss Per Share $0.64", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-02T14:33:00.000+02:00", "replies_count": 0, "uuid": "493c4f69045b6f52180398bc7bb6ea57f8779965"}, "author": "", "url": "https://www.reuters.com/article/brief-reata-pharmaceuticals-inc-announce/brief-reata-pharmaceuticals-inc-announces-q4-loss-per-share-0-64-idUSASB0C8LL", "ord_in_thread": 0, "title": "BRIEF-Reata Pharmaceuticals Inc. Announces Q4 Loss Per Share $0.64", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-reata pharmaceuticals inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "reata pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 2, 2018 / 12:34 PM / Updated 9 minutes ago BRIEF-Reata Pharmaceuticals Inc. Announces Q4 Loss Per Share $0.64 Reuters Staff March 2 (Reuters) - Reata Pharmaceuticals Inc: * REATA PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS * Q4 LOSS PER SHARE $0.64 * AS OF DECEMBER 31, 2017, COMPANY HAD $129.8 MILLION IN CASH AND CASH EQUIVALENTS * REATA PHARMACEUTICALS- BELIEVE EXISTING CASH AND CASH EQUIVALENTS, AVAILABLE DEBT AND EXPECTED MILESTONE WILL BE SUFFICIENT TO FUND INTO H2 2019 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)", "external_links": [], "published": "2018-03-02T14:33:00.000+02:00", "crawled": "2018-03-02T14:51:43.010+02:00", "highlightTitle": ""}